| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.08 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.08 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.09 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.29 | 0.09 |
| mRNA | selumetinib:piperlongumine (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.061 | 0.09 |
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.092 | 0.09 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.056 | 0.09 |